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2Abstract15
Gene expression from both parental genomes is required for completion of embryogenesis.16
Differential methylation of each parental genome has been observed in mouse and human17
preimplantation embryos. It is possible that these differences in methylation affect the level18
of gene transcripts from each parental genome in early developing embryos. The aim of this19
study was to investigate if there is a parent specific pattern of BRCA1 expression in human20
embryos and to examine if this affects embryo development when the embryo carries a21
BRCA1 or BRCA2 pathogenic variant.22
Differential parental expression of ACTB, SNRPN, H19 and BRCA1 was semi-quantitatively23
analysed by mini-sequencing in 95 human preimplantation embryos obtained from 1524
couples undergoing preimplantation genetic diagnosis (PGD).25
BRCA1 was shown to be differentially expressed favouring the paternal transcript in early26
developing embryos. Methylation specific PCR showed a variable methylation profile of27
BRCA1 promoter region at different stages of embryonic development. Embryos carrying28
paternally inherited BRCA1 or 2 pathogenic variants were shown to develop more slowly29
compared to the embryos with maternally inherited BRCA1 or 2 pathogenic variants.30
This study suggests that differential demethylation of the parental genomes can influence31
the early development of preimplantation embryos.32
33
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4Summary37
Expression of maternal and paternal genes is required for the completion of embryogenesis.38
The differential methylation of the parental genomes observed in human preimplantation39
embryos may lead to differential expression of parental genes. In case of the transmission of40
any parental pathogenic variant to the embryo, this differential gene expression may cause41
embryonic developmental delays.42
This study has shown that the parental alleles of BRCA1 are differentially expressed43
depending on the embryonic development stage. Differential BRCA1 expression is associated44
with the differential methylation status of BRCA1. Furthermore, embryos carrying paternally45
inherited BRCA1 or 2 pathogenic variants were shown to develop slower compared to the46
embryos with maternally inherited BRCA1 or 2 pathogenic variants. Hence, differential gene47
expression can influence the early development of preimplantation embryos, depending on48
the parental origin of the BRCA1 or 2 pathogenic variant. Further extrapolation of this data49
suggests that paternally inherited BRCA1 or 2 pathogenic variants leads to embryos with50
poor viability compared to embryos with maternally inherited pathogenic variants.51
5Introduction52
Preimplantation embryo development follows a series of critical events, deprogramming of53
the genomes of sperm and egg and remarkable reprogramming of gene expression occurs to54
activate the embryonic genome. With the exception of imprinted loci, the expression of both55
maternal and paternal copies of genes is required for the completion of embryogenesis [1].56
In mice, the genome of the oocyte is markedly undermethylated compared to the sperm [2].57
Upon fertilization, mammalian zygotes (including humans) undergo genome-wide58
demethylation to establish the pluripotency of the newly developing embryo [2]. Selective59
demethylation of the male pronucleus occurs upon fertilization [3-9]. In contrast to the male60
pronucleus, demethylation of the female mouse pronucleus starts with the first cleavage61
divisions [2, 3, 7-10]. Recent genome-wide DNA methylation studies have reported a wave of62
demethylation in early preimplantation embryos. Throughout early embryonic development63
a differential methylation pattern is maintained in the majority of the differentially64
methylated regions in imprinted genes, although some show stage-specific changes [11].65
Repetitive elements, housekeeping genes and genes controlling pluripotency or66
differentiation have been reported to have specific methylation patterns during embryo67
development [12, 13].68
We hypothesize that, during the transition of demethylation and deprogramming in69
preimplantation embryo development, there is differential expression of parental alleles in70
certain genes that are not imprinted genes. The differential expression of parental alleles71
arises due to variation in the timing of demethylation and the level of methylation of each72
parental genome. Changes in the methylation patterns of BRCA1 have been reported in early73
developing preimplantation embryos [14]. If there is differential demethylation and74
6remethylation of non-imprinted genes of maternal and paternal genomes during early75
development, then the level of transcription from each parental genome may also be76
different. Thus, when a pathogenic variant is present, the differential level of mutant and77
normal transcripts available for translation in the early embryo will be determined by the78
parental origin of the variant in the embryo. This in turn suggests that the effect of79
inheritance of a variant may vary in the early embryo, depending on whether it was80
transmitted from the maternal or paternal genome.81
We therefore sought to characterize differential parental gene expression in human82
preimplantation embryos obtained from patients undergoing preimplantation genetic83
diagnosis (PGD) and to investigate the possible effect of a pathogenic variant on embryo84
development depending on the parental inheritance of the variant.85
Methods86
Sample collection and processing87
This study was licensed by the Human Fertilization and Embryology Authority (Reference:88
RO113) and ethical approval was granted by the National Research Ethics Service, Research89
Ethics Committee (Reference: 10/H0709/26). Whole blood and surplus embryos were90
collected from couples who had given informed consent following PGD treatments for a91
variety of monogenic disorders.92
Ovarian reserve tests and gonadotrophin stimulation were performed as described93
previously [15]. Briefly, immature oocytes were matured in G-IVF Plus medium (Vitrolife)94
within 4 hours of collection. Intracytoplasmic sperm injection was performed approximately95
40 hours post hCGH injection. Fertilisation was assessed at 16-20 hours post insemination96
7and the presence of two pronuclei and polar bodies indicated normally fertilized oocytes97
[16]. Embryos were cultured in G-1/G-2 PLUS media (Vitrolife, UK). Preimplantation embryos98
were graded according to Bolton and colleagues [17]. Those embryos diagnosed as affected99
following preimplantation genetic diagnosis (PGD) or not suitable for transfer were collected100
on day 6 post fertilisation, in order to be used for this project. Each embryo was washed and101
transferred in phosphate buffered saline with 0.1% polyvinyl alcohol solution (PBS/PVA,102
Sigma, USA) and 0.3U/µl RNasin plus RNAse inhibitor (Promega, UK).103
Genotyping couples104
DNA extracted from whole blood from the couple was sequenced (BigDye® Terminator v3.1105
Cycle Sequencing, ABI, UK) for exonic regions of GAPDH, ACTB, UBE3A, SNRPN, IGF2, H19106
and BRCA1 to identify informative single nucleotide polymorphisms (SNPs) between the107
partners (Supplemental table I). A couple was defined as fully-informative for an SNP when108
each partner was homozygous for different alleles, whereas a couple was defined as semi-109
informative when one partner was homozygous and the other was heterozygous with one110
shared allele at the SNP.111
DNA and RNA extraction from embryos112
DNA and RNA from embryos were extracted using the AllPrep DNA/RNA micro kit (Qiagen,113
UK). The quality of RNA was assessed using the RNA 6000 Pico kit (Agilent, UK) on a114
Eukaryote Total RNA Pico Series II chip using the Agilent 2100 Bioanalyzer (Agilent, USA).115
Analysis of differential gene expression116
Reverse transcription of RNA obtained from the embryos was performed using the117
SuperScript™ III first-strand synthesis system for RT-PCR (Invitrogen, UK). DNA118
8contamination was identified by multiplex PCR (Qiagen, UK) using two markers (Eurogentec,119
UK) D19S112 and APOC2. These markers were selected to detect DNA contamination since120
they amplify an exonic as well as an intronic region. Additionally, these markers were used121
due to the high heterozygosity.122
SNaPshot Minisequencing assay sensitivity123
Differential expression of parental transcripts using RNA samples was analysed semi-124
quantitatively on the previously identified informative and semi-informative SNPs by125
SNaPshot minisequencing assay (Applied Biosystems, UK) (Supplemental table II).126
Differential expression of one parental transcript relative to the other was defined as an127
allele peak height ratio greater than 1:2. Monoallelic or preferential allelic expression of a128
transcript was only considered in embryos where both parental alleles could be identified in129
the analysed SNP. If an allele shared by each parent was expressed in the embryo, the130
sample was excluded from the analysis. Statistical analysis was performed by Student’s T-131
test using GraphPad prism v6 software. The quantitative difference between each parental132
allele in the embryos identified by mini-sequencing was validated by real time PCR with133
subsequent high resolution melting analysis (Roche, UK).134
Chromosomal copy number analysis135
The chromosome copy number of the genes (chromosomes7, 11, 15 and 17) was analysed using136
DNA to ensure that the differential expression detected is not due to an aneuploidy in the137
embryo. The copy number of chromosomes 7, 11, 15 and 17 was determined by haplotype138
analysis. Polymorphic markers that are on the same chromosomes with the genes analysed,139
ACTB, SNRPN, H19 and BRCA1, and that were available in our laboratory were used to140
determine the chromosome copy number. Analysis of the copy number of chromosome 7141
9were linked to CFTR (D7S2420, D7S2459, D7S486), chromosome 11 markers were linked to142
HBB (D11S1338, D11S1997, D11S4147), chromosome 15 to FBN1 (D15S992, D15S123,143
D15S94) and chromosome 17 to BRCA1 (D17S579, D17S1789, D17S1353, D17S841). The144
copy number of the chromosomes was scored only if the origin of the parental alleles at that145
locus could be distinguished. In these cases, if only one parental allele was detected, the146
embryo was considered to have lost the copy of the chromosome harbouring the missing147
allele. Embryos were considered to have gained a chromosome when three alleles were148
detected. An isodisomy of the chromosome could not be detected in the embryo using this149
method.150
A subset of embryos was also analysed by array comparative genomic hybridization (aCGH)151
using the 24Sure system, following whole genome amplification (BlueGnome, UK). The slides152
were scanned using ScanArray Express (Perkin Elmer, USA) and the arrays were analysed153
using Bluefuse Multi analysis software v.2.6 (BlueGnome, UK). The cut-off of the log2 ratio154
fluorescent test signal over the control DNA was set as +0.3 for the gain and -0.3 for the loss155
of a chromosome by the software.156
Methylation studies157
The methylation status of ACTB, H19 and BRCA1 was analysed in a subset of embryos. The158
EpiTect Bisulfite conversion kit (Qiagen, UK) was used for DNA treatment. A set of outer159
primers with no CpG dinucleotides was designed for ACTB, H19 and BRCA1 (Supplemental160
Table III). Two sets of inner primers resulting in PCR products of different sizes directed to161
the methylated and unmethylated sequences were used for the promoter regions of ACTB,162
H19 and BRCA1 [18].163
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Statistical Analyses: Embryos with BRCA1 or 2 pathogenic variants and preimplantation164
embryo development165
The developmental stage of all the embryos with BRCA1 or 2 pathogenic variants was166
examined on day 5/6 post fertilization and related to the parental inheritance of the variant.167
Statistical analysis was performed to investigate the difference between the developmental168
stage of embryos with paternally inherited BRCA1 or 2 pathogenic variants and the169
maternally inherited BRCA1 or 2 pathogenic variants by Chi-square test using GraphPad170
prism software v6.171
Results172
Genotyping analysis173
Parental genotyping by sequencing of seven genes identified informative SNPs between 15174
partners that enabled detection of heterozygous embryos in four genes (Table I).175
Haplotyping analysis was performed to determine the copy number of chromosomes 7, 11,176
15 and 17 in embryos. The detailed results are listed in table II. Of these embryos, 26 were177
also analysed by aCGH. Twelve embryos were shown to be euploid and the rest of the178
embryos showed various aneuploidies. Only two of these embryos (embryo 69 and 72)179
showed aneuploidies for the chromosomes of interest (gain of chromosome 17) and these180
embryos were excluded from the analysis (Table II).181
Minisequencing assay sensitivity for allelic imbalance182
The sensitivity of the mini-sequencing analysis was validated by real time PCR. Amplification183
of cDNA from the embryos showed that the mean Cq values for the start of the exponential184
phase of amplification were 36 for ACTB, 34 for SNRPN, 41 for H19 and 35 for BRCA1.185
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Therefore, PCR prior to mini-sequencing analysis was stopped before the exponential phase186
was reached. High resolution melting analysis of all the PCR products from embryos187
confirmed the allelic imbalances identified by minisequencing.188
Differential gene expression in preimplantation embryos189
A total of 95 embryos were analysed to establish the parental expression profiles of ACTB,190
SNRPN, H19 and BRCA1. A summary of the results is shown in table I and figure I. The191
expression level of maternal and paternal transcripts of ACTB was similar for all eleven192
embryos analysed for this gene.193
Minisequencing analysis of imprinted gene transcripts showed that paternal transcript of194
SNRPN predominated in more than half of the embryos regardless of their developmental195
stage (*p=0.01; 56.5%, 13/23, figures I and II). Monoallelic expression of paternal SNRPN196
transcript was observed in 69% (9/13) of these embryos. As the embryos reached later197
stages of development, differential expression favouring the paternal SNRPN transcript198
increased from 61% (8/13) at cleavage and morula stages to 70% (7/10) for the blastocyst199
stage embryos.200
Unlike SNRPN, H19 was not readily detected in human preimplantation embryos (31%,201
15/48). One embryo was excluded from the analysis since it was shown to have only the202
maternal copy of chromosome 11 by haplotyping. This accounted for the detection of only203
the maternal H19 transcript by the SNapShot assay. Overall, 60% (9/14) of the embryos204
expressed predominantly the maternal H19 transcript with 78% (7/9) being strictly205
monoallelic for the maternal transcript. Preferential expression of the maternal H19206
transcript was observed to be 50% (2/4) at cleavage, 66% (4/6) in morula and 75% (3/4) in207
blastocyst stage embryos.208
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Two SNPs, located in exon 11 and exon 12, were analysed to investigate differential209
expression of parental BRCA1 transcripts. Thirteen per cent (10/75) of the embryos analysed210
were excluded from the analysis since the differential expression was not concordant at211
these two SNPs. Two embryos were excluded from the analysis since they showed a gain of212
chromosome 17, reflecting the preferential BRCA1 expression by the SNaPshot assay.213
Differential BRCA1 expression in the embryos was 66% (10/15) at cleavage, 55% (10/18) at214
morula and 50% (7/14) at the blastocyst stage. Overall, there were significantly more215
embryos with elevated expression of paternal BRCA1 transcripts compared to embryos with216
increased expression of maternal transcripts, regardless of the developmental stage217
(*p=0.03, Figures I and II).218
Differential methylation analysis219
Methylation analysis was performed by bisulfite conversion, followed by methylation-220
specific PCR. Due to insufficient starting material, the amount of DNA obtained from a single221
embryo and the bisulfite treatment being deleterious for DNA, sequencing analysis on the222
converted DNA could not be performed. The promoter regions of three genes, ACTB, H19223
and BRCA1, were amplified by nested PCR. When monoallelic expression of one parental224
transcript was observed by SNaPshot analysis, a hemi-methylated profile was expected to be225
observed since only one parental transcript is present. When both parental transcripts were226
expressed at similar levels by SNaPshot analysis, an unmethylated profile was expected to be227
observed, representing both parental transcripts at similar levels. Since allele specific228
methylation was not studied, it is not possible to draw a definite conclusion as to whether229
the methylation status was the reason for differential gene expression.230
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Methylation analysis of ACTB in five embryos showed that these embryos were231
unmethylated, which supports the expression profile observed by SNaPshot analysis (Figure232
III). Methylation analysis of 3/8 embryos confirmed the differential H19 expression. Of these233
embryos, two were hemi-methylated. These embryos also showed monoallelic expression of234
H19 transcript. One embryo was unmethylated, and this supported the biallelic expression of235
H19 transcripts by the minisequencing assay. In 5/8 embryos differential expression of the236
parental transcripts did not relate to the methylation status. The hemi-methylated profile of237
BRCA1 confirmed differential expression of parental transcripts in 58% (18/31) of the238
embryos.239
Development of embryos with BRCA1 and BRCA2 variants240
Following PGD for BRCA1 and BRCA2 in six couples, 31 embryos were identified with a241
BRCA1 or BRCA2 pathogenic variants. Half of the embryos with paternally-transmitted242
BRCA1 germline pathogenic variants (8/16) were arrested at the cleavage stage. Only 12.5%243
(2/16) of these embryos reached the blastocyst stage 5 days post fertilization. Embryos with244
maternally-inherited BRCA1 variants developed at a significantly faster rate (8/15, 53% at245
blastocyst stage, p=0.01) compared to the embryos with paternally inherited BRCA1 and246
BRCA2 pathogenic variants (Figure IV).247
Discussion248
Differential expression249
This study showed that similar levels of parental ACTB transcripts were expressed in human250
embryos. The paternally imprinted gene H19 was not always detected in embryos. Some251
studies have reported the detection of both parental alleles in slow growing embryos or252
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morphologically poor embryos [19], whereas some did not detect H19 at all [20]. In this253
study, H19 was detected in 31% (15/48) of the embryos. Although biallelic expression of the254
H19 transcript (7/14) was detected in half of the embryos confirming previously published255
reports [21], preferential expression of maternal H19 transcripts was observed in the256
majority of the embryos. Although it is well accepted that H19 is a paternally imprinted257
gene, expression of both parental H19 alleles has been reported in the human oocytes and258
preimplantation embryos. Studies have suggested that developmentally delayed embryos259
show an unexpected expression and methylation profile [19]. In this study, embryos with260
similar parental expression of H19 developed at a slower rate where seven embryos were261
between 5-10 cell stage and two were at morula stage on day 5/6 post fertilisation.262
Additionally, all of the embryos that reached blastocyst stage showed opposing patterns of263
parental expression for these two imprinted genes. This observation supports the finding of264
Khoueiry and colleagues (2012) who reported that slow developing embryos had a balanced265
pattern of methylated and unmethylated strands of H19DMR [21].266
The imprinting of SNRPN was not completed in the early developing preimplantation267
embryos, such that the maternal SNRPN transcript was detected in 60% (9/15) of the268
embryos, as reported previously [20, 22]. The unexpected expression of maternal SNRPN269
alleles could be due to the on-going maternal mRNA degradation in these embryos, whereas270
the paternal H19 transcripts could be caused by partial resetting of H19 in the sperm [19].271
The onset of the monoallelic expression of these genes might be at a later stage in human272
embryos or the time of the monoallelic expression could be variable among embryos. It has273
been reported that the time of the monoallelic expression of the imprinted genes, such as274
IGF2, SNPRN and MEST, varies in mouse embryos [22, 23]. Developmentally delayed275
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embryos were shown to have unusual expression and methylation profiles [19, 21]. This was276
also observed in our study, where 20% (3/15) of slow developing embryos had similar277
expression levels of H19 and 39% (9/23) of slow developing embryos had similar parental278
levels of SNRPN transcripts. None of these embryos reached the blastocyst stage. It is also279
possible that assisted reproductive technology techniques lower the level of methylation for280
the imprinted genes [19, 24-26], causing the unexpected expression of transcripts [27].281
In this study, differential expression of paternal BRCA1 transcript was observed in embryos.282
This preferential expression was more prevalent in cleavage stage embryos. As the embryos283
developed to the blastocyst stage, differential expression of BRCA1 was reduced. In 13% of284
the embryos, differential BRCA1 expression could not be determined since the expression285
profiles for the two SNPs analysed were not concordant. BRCA1 is known to undergo286
alternative splicing in a number of its exons, forming isoforms that skip exon 5, exons 2-10,287
exons 9-11, exon 11 only, exons 14-17 and exons 14-18 [28, 29]. Alternative splicing of exon288
11 yields a full-length isoform and also shorter isoforms either through the use of an289
alternative intra-exonic splice donor site [29-31] or through complete skipping of exon 11.290
Therefore, if one of these isoforms was present in the embryos analysed in this study,291
differences in the expression profiles of BRCA1 in exon 11 and exon 12 may have arisen.292
The methylation analysis showed that preferential expression observed in H19 and BRCA1293
may be due to the methylation status of the parental transcripts. A gradual demethylation294
was previously observed for BRCA1 during cleavage divisions of human embryos where295
approximately 30% of the methylated BRCA1 residues remained up to the blastocyst stage296
[14]. A recently published study also showed that monoallelic as well as biallelic expression297
was detected in human primary fibroblasts [32]. They reported that each cell mostly298
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expressed one allele. The abundance of the cellular transcripts and the monoallelic299
expression could account for phenotypic variability in humans including penetrance and300
expressivity of a dominant developmental disorder, or cellular heterogeneity in cancers and301
predisposition to a complex phenotype [32].302
Development of embryos with BRCA1 and BRCA2 pathogenic variants303
The development of the embryos with BRCA1 or 2 pathogenic variants were investigated in304
six couples undergoing PGD. Three males and three females with BRCA1 or 2 pathogenic305
variants opted for PGD. Two of the male partners had BRCA1 pathogenic variants and one306
had BRCA2 pathogenic variant. The female partner of the rest of the couples undergoing307
PGD had BRCA1 pathogenic variants. The majority of the embryos with paternally inherited308
BRCA1 or 2 pathogenic variants (8 embryos with BRCA1 and 8 embryos with BRCA2309
pathogenic variants, respectively) were shown to arrest at the cleavage between 4 to 10 cell310
stages (50%). Only 38% of the embryos developed to the morula stage and only 12.5% of the311
embryos reached the blastocyst stage. Embryos with paternally BRCA1 and BRCA2 inherited312
pathogenic variants (16 embryos) were shown to develop significantly slower compared to313
embryos with maternally inherited variants (15 embryos, *p=0.01). Since the paternal314
genome undergoes a rapid demethylation starting at the early stages of preimplantation315
embryos, embryos with paternally inherited BRCA1 and BRCA2 pathogenic variants and316
defective homologous recombination pathways may be prevented from developing to the317
later stages of preimplantation development. However, embryos with maternally inherited318
BRCA1 pathogenic variants may compensate for the variant and initiate homologous319
recombination repair through paternal transcripts that were free from the variant.320
Therefore, when the embryos are carrying a paternally inherited BRCA1 or BRCA2321
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pathogenic variants, it may be more prone to embryonic lethality during cleavage divisions.322
Thus we speculate that less viable embryos with paternally inherited BRCA1 or 2 pathogenic323
variants are produced compared to the maternally inherited BRCA1 or 2 pathogenic variants.324
Therefore, we assume that there are more adults with maternally inherited BRCA1 or 2325
pathogenic variants. The higher number of maternally inherited BRCA1 or 2 variants was also326
reported previously [33, 34]. Although these articles were evaluating the risk of cancer and327
the onset of cancer depending on the parental origin of the BRCA1 or 2 variants, their data328
showed that there were more patients with maternally inherited BRCA1 or 2 variants [33,329
34]. Once the genome wide demethylation of genes is completed during cleavage divisions,330
we assume that embryos with maternally and paternally inherited BRCA1 or 2 variants have331
similar chances of implantation and pregnancy.332
Conclusion and future perspectives333
The main limitation of this study was the small number of embryos analysed due to the334
scarcity of the human embryos. However, even with this small number of embryos, the data335
shows significant outcome relating gene expression with development of preimplantation336
embryos. This study showed that SNRPN, H19 and BRCA1 transcripts were differentially337
expressed in human embryos. The presence of a BRCA1 or 2 pathogenic variants inherited338
from the paternal genome had a greater detrimental effect on the development of the339
embryo to blastocyst compared to pathogenic variants inherited from the maternal genome.340
This may stem from differences in methylation patterns of the parental genomes in341
embryos. Therefore, the contribution of the paternal genome in the preimplantation embryo342
development may be vital, especially in the early stages. Further extrapolation of this data343
suggests that the risk of transmitting a BRCA1 or 2 pathogenic variants may be altered by the344
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parental origin of the variant. Paternally transmitted BRCA1 or 2 pathogenic mutations are345
more likely to result in embryos that fail to reach blastocyst thereby limiting the346
implantation potential of these embryos. Consequently this may lower the overall risk of347
males with BRCA1 or 2 mutations having children who have inherited their pathogenic348
mutation.349
350
351
352
.For couples undergoing PGD for BRCA 1 or 2, where the male partner carries the353
pathogenic mutation354
355
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Titles and legends to tables and figures456
Table I Summary of differential expression analysis.457
The genes analysed for differential expression, percentage of informative haplotypes where458
each parental allele was distinguished and the percentage of embryos with differential gene459
expression favouring the paternal and maternal transcripts are listed. BRCA1 was analysed at460
two loci and the results shown here were collective from both loci. In ten embryos461
differential expression of BRCA1 at two loci did not agree and these were not included in the462
analysis. *Only the paternal expression of SNRPN was observed in 9/13 embryos and only463
the maternal expression of H19 was observed in 7/9 embryos.464
Genes
analysed
Number of embryos
included for the
study
% of informative
haplotypes (number
of embryos)
% of embryos showing
differential expression favouring:
(number of embryos)
Paternal Maternal Similar
ACTB 30 36.7 (11) 0 0 100 (11)
SNRPN 34 67 (23) 56.5 (13)* 17 (4) 26 (6)
H19 48 33 (15) 13 (2) 60 (9)* 26 (4)
BRCA1 75 64 (49) 58 (29) 19 (9) 22 (11)
465
466
467
468
469
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Table II Table summarising the embryos analysed for haplotyping analysis for the470
chromosomes of 7 (CFTR), 11 (HBB), 15 (FBN1) and 17 (BRCA1).471
Number of embryos included in the haplotyping analysis with the percentage of informative472
haplotypes and heterozygote embryos are summarised. The percentage of inconclusive473
analysis due to amplification failure was also shown.474
Chromosomes analysed Number of
embryos included
for the study
% of informative
haplotypes
(number of
embryos)
% of heterozygous
embryos (number
of embryo)
% of embryos
with
amplification
failure (number
of embryo)
CFTR 30 86.7 (26) 86.7 (26) 13 (4)
HBB 34 53 (18) 94 (17) 26 (9)
FBN1 48 25 (12) 91 (11) 4 (2)
BRCA1 75 68 (51) 94 (48) 19 (21)
475
476
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Titles and legends to figures477
Figure I Overall differential expression of paternal and maternal transcripts for four genes478
in human embryos.479
SNRPN BRCA1H19ACTB
480
It was shown that there was no significance in the differential expression of parental481
transcripts for ACTB (p=0.2). Paternal SNRPN transcripts were expressed at significantly482
higher levels relative to the maternal transcripts (*p= 0.01) in embryos. Although higher483
levels of maternal H19 transcripts were detected in embryos, this was not significant (p=0.4).484
The differential expression of paternal BRCA1 expression was shown to be significant relative485
to the maternal transcripts (*p= 0.03) in the embryos.486
487
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Figure II GeneScan™ fragment size analysis result panels showing differential gene488
expression of: a) ACTB from couple D. The panel shows the embryo number 10, 12 and 14489
(all heterozygote for G and A) with similar expression levels of the parental copies of the SNP490
analysed, female partner (homozygote for A), male partner (heterozygote G and A) of couple491
A and negative control with no DNA. b) SNRPN from couple A. The panel shows the embryo492
number 1 (heterozygote for G and A) with increased expression of the paternal copy of the493
SNP analysed, female partner (heterozygote for G and A), male partner (homozygote for G)494
of couple A and negative control with no DNA. c) H19 from couple K. The panel shows the495
embryo number 74 (maternally expressed allele only, homozygote for C) and 80496
(heterozygote for C and T) with increased expression of the maternal copy of the SNP497
analysed, female partner (heterozygote for C and T), male partner (homozygote for T) and498
negative control with no DNA. d) BRCA1 from couple C. The panel shows the embryo499
number 5 and 6 (both heterozygote for C and T) with considerably increased expression of500
the paternal copy of the SNP analysed, female partner (heterozygote for C and T), male501
partner (homozygote for T) and negative control with no DNA. The panels show the alleles502
expressed in the embryo and the allele of the SNP of the female and male partner of the503
couple. The peak heights of the alleles are shown in parentheses.504
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Figure III Agarose gel electrophoresis of embryos showing partial methylation for a) H19 and507
b) BRCA1.508
a) b)
509
Lanes 1 for images a) and b) represent 100 base pair ladder and the rest of the lanes represent the510
methylation PCR product results of DNA obtained from embryos following bisulfite conversion. Embryo511
numbers are labelled for each lane and the PCR directed towards the methylated DNA is represented512
as “methylated” and the unmethylated DNA as “unmethylated”.513
514
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Figure VI Developmental rate of embryos carrying paternally inherited BRCA1 or 2515
mutations compared to maternally inherited BRCA1 or 2 mutations.516
517
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518
Significantly fewer embryos developed to the later stages of preimplantation development519
(morula and blastocyst stages) compared to the embryos carrying maternally inherited520
mutations (*p=0.01).521
522
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Supplemental Tables523
Supplemental Table 1 Primer details used for differential gene expression analysis in524
embryos.525
a) Primer names, sequences, chromosomal locations and PCR product sizes are listed.526
Sequences were obtained from Ensembl; ACTB (ENSG00000075624, Ensembl release 60),527
SNRPN (ENSG00000128739, Ensembl release 60), H19 (ENSG00000130600, Ensembl release528
60) and BRCA1 (ENSG00000012048, Ensembl release 60) on the Ensembl genome browser.529
530
Primer Primer sequence Locus
Product
size (bp)
ACTBex7 F 5'-AACACTGGCTCGTGTGACAA-3'
7:5568239:5568860 236
ACTBex7 R 5'-GGGGTGTTGAAGGTCTCAAA-3'
BRCA1ex11 F 5'-TCAAAGGAGGCTCTAGGTTTTG-3'
17:41244039:41244860 373
BRCA1ex11 R 5'-GCTTGAATGTTTTCATCACTGG-3'
BRCA1ex12 F 5'-TCATTTAATGGAAAGCTTCTCAAAG-3' 17:41234330:41234
954
290
BRCA1ex12R 5'-AAAGGGGAAGGAAAGAATTTTG-3'
BRCA1ex12 RNA
only F 5'-AGCAGGAAATGGCTGAACTA-3' 17:41234126:41234
745
130
BRCA1ex12 RNA
only R 5'-TCTGATGTGCTTTGTTCTGG-3'
29
531
SNRPNex12 F 5'- CCTCTGCAGGCTCCATCTAC-3'
15:25219149:25219768 151
SNRPNex12 R 5'- ATTGCTGTTCCACCAAATCC-3'
H19 F 5'-TTACTTCCTCCACGGAGTCG-3'
11:2016950:2017675 340
H19 R 5'-GACACGTGGGTGGGATGG-3'
30
Supplemental Table 2 Sequences of primers used in minisequencing for differential532
gene expression analyses.533
534
535
Primer name Primer sequence
MS_BRCAex11_ rs16941 5'-CATTAGAGAAAATGTTTTTAAAAG-3'
MS_BRCAex12_ rs1060915 5'-CCCTTCCATCATAAGTGACTC-3'
MS_ACTBex7_rs852423 5'-CATTGTTTCTAGGAGAACC-3'
MS_SNRPNex12_rs75184959 5'-ATGATCTGTAAGGCAGAGAT-3'
MS_H19_rs2839701 5'-ACTCAGGAATCGGCTCT-3'
31
Supplemental table 3 Sequences of primers used in methylation specific PCR.536
Primer name Primer sequence Expected product
size (bp)
ACTB_promoter_outer_F GATTTGATTGATTATT TTATGAAGAT TTTT
210
ACTB_promoter_outer_R CTCATTACCAATAATAGATAACCTA
ACTB_promoter_methylated_F CGCGGTTATAGTTTTATTATTACGGTCGAG
96
ACTB_promoter_methylated_R ACCATCTCTTACTCGAAATCCAAAACGACG
ACTB_promoter_unmethylated_F TGTGGTTATA GTTTTATTAT TATGGTTGAG
120
ACTB_promoter_unmethylated_R ACCATCAAACAACTCATAACTCTTCTCCAA
H19_promoter_outer_F GGTTTTTAGATAGGAAAGTGGT
185
H19_promoter_outer_R AATAAAATACTAAAAAACAAAAAAAAATAC
H19_promoter_ unmethylated_F TTGTGAATGGGATTGGGGTGTTTAGTGGTT
124
H19_promoter_ unmethylated_R CACAAACCCCCTAATAAACACAATACC
H19_promoter_methylated_F GATCGGGGTGTTTAGCGGTTGTGGGGATTT
134
H19_promoter_ methylated_R CGCAAACCCCCTAATAAACGCGATACC
BRCA1_promoter_outer_F TTTTTTTATTTTTTGATTGTATTTTGATTT
184
BRCA1_promoter_R TTATCTAAAAAACCCCACAACCTATCCCCC
BRCA1_promoter_unmethylated_F TTGGTTTTTGTGGTAATGGAAAAGTGT
86
BRCA1_promoter_unmethylated_R CAAAAAATCTCAACAAACTCACACCA
32
BRCA1_promoter_methylated_F TCGTGGTAACGGAAAAGCGCGGGAATTA
75
BRCA1_promoter_methylated_R AAATCTCAACGAACTCACGCCGCGCAATCG
537
